The risk of second primary malignancies in colorectal cancer patients using calcium channel blockers
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | SCIENTIFIC REPORTS |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.nature.com/articles/s41598-023-29535-7 |
| Doi | http://dx.doi.org/10.1038/s41598-023-29535-7 |
| Keywords | colorectal cancer; calcium channel blockers; second primary malignancies |
| Attached files | |
| Description | Calcium channel blockers are among the most commonly used agents in the treatment of cardiovascular diseases. There are several known side-effects associated with their long-term use, whereas other potential adverse effects are yet to be proven. This study aims to evaluate the association between calcium channel blockers exposure and the incidence of second primary malignancy. We established a cohort of 1401 patients with colorectal cancer diagnosed in our institution between January 2003 and December 2016. Patients were followed-up until December 2020. The tumor characteristics and basic clinical data including medication information were obtained from the hospital information system database. Second malignancy was detected in 301 patients (21.5%), and occurred in 27.8% of patients who used calcium channel blockers compared to only 19.9% among non-users. Their use was associated with an increased incidence of bladder cancer in particular. Subanalysis of patients with second malignancy displayed a higher proportion of right-sided colon cancer compared to rectal carcinoma in non-users. Survival analysis revealed significantly better outcomes in early-stage colorectal cancer patients without a history of calcium channel blockers treatment or second primary malignancy. |
| Related projects: |
|